Potential Importance of Leucine in Treatment of Obesity and the Metabolic Syndrome

Donald K. Layman*† and Denise A. Walker‡

*Department of Food Science and Human Nutrition and †Division of Nutritional Sciences, University of Illinois, Urbana, IL 61801

ABSTRACT Diets with total protein intake >1.5 g·kg⁻¹·d⁻¹ and carbohydrate intake <150 g·d⁻¹ are effective for treatment of obesity, type 2 diabetes, and the Metabolic Syndrome. These diets improve body composition and enhance glycemic control. During weight loss, protein-rich diets reduce loss of lean tissue and increase loss of body fat. Specific mechanisms to explain each of these clinical outcomes remain to be fully elucidated. We propose that keys to understanding the relationship between dietary protein and carbohydrates are the relationships between the branched-chain amino acid leucine and insulin and glucose metabolism. Leucine is known to interact with the insulin signaling pathway to stimulate downstream signal control of protein synthesis, resulting in maintenance of muscle protein during periods of restricted energy intake. Leucine also appears to modulate insulin signaling and glucose use by skeletal muscle. Whereas total protein is important in providing substrates for gluconeogenesis, leucine appears to regulate oxidative use of glucose by skeletal muscle through stimulation of glucose recycling via the glucose-alanine cycle. These mechanisms produce protein sparing and provide a stable glucose environment with low insulin responses during energy-restricted periods. J. Nutr. 136: 319S–323S, 2006.

KEY WORDS: • diabetes • glycemic control • insulin • protein synthesis

Evidence is accumulating that diets with higher protein and reduced carbohydrates are beneficial for weight loss (1–7). These studies report that diets with reduced ratios of carbohydrates to protein increase weight loss (1–3,5,6), increase loss of body fat (2,3,5), and reduce loss of lean tissue (1,3,5,7). We proposed that the beneficial effects of a higher protein diet included the roles of leucine in sparing muscle protein loss and enhancing glycemic control (8,9). This article will review metabolic roles of leucine and examine some of the clinical trials with higher protein diets and weight loss.

The BCAA leucine plays multiple roles in metabolism beyond the minimum requirement as an essential substrate for synthesis of new proteins (8,10). These roles include a key regulator of translation initiation of protein synthesis in skeletal muscle (11), a modulator of insulin/PI3-kinase signaling (12,13), a fuel for skeletal muscle (14), and a primary nitrogen donor for production of alanine and glutamine in skeletal muscle (15). The potential for leucine to impact protein synthesis, insulin signaling, and production of alanine and glutamine is dependent on dietary intake and increasing leucine concentration in skeletal muscle (8,10,13).

The multiple roles of leucine are, at least in part, associated with absence of the branched-chain aminotransferase enzyme in liver, resulting in an enriched supply of the BCAA appearing in blood (8,10,16). Dietary BCAAs reach the blood virtually unaltered from levels in the diet, allowing leucine to reach skeletal muscle in direct proportion to dietary intakes. This is a striking metabolic difference for these amino acids, which account for >20% of total dietary protein. Using the traditional thinking that dietary protein requirements should be defined by efficiency of nitrogen handling, we are left to ponder why the body evolved to metabolize 20% of total amino acids (and total nitrogen) in peripheral tissues? We hypothesized that this unique treatment of the BCAA and specifically leucine provides an important signal of dietary quality for skeletal muscle (8,10).

One of the first reports that leucine metabolism was optimized at dietary intakes greater than the minimum recommended dietary allowance (RDA) was provided by the MIT group (17). Using stable isotopes and measurement of whole-body leucine metabolism, daily leucine usage was determined to be >6 g·d⁻¹ and ~3 times higher than recommended dietary

---

1 Published in a supplement to The Journal of Nutrition. Presented at the conference “Symposium on Branched-Chain Amino Acids,” held May 25–24, 2005 in Versailles, France. The conference was sponsored by Ajinomoto USA, Inc. The organizing committee for the symposium and guest editors for the supplement were Luc Cynober, Robert A. Harris, Dennis M. Bier, John O. Holloszy, Sidney M. Morris, Jr., and Yoshiharu Shimomura. Guest editor disclosure: L. Cynober, R. A. Harris, D. M. Bier, J. O. Holloszy, S. M. Morris, Y. Shimomura: expenses for travel to BCAA meeting paid by Ajinomoto USA; D. M. Bier: consults for Ajinomoto USA; S. M. Morris: received compensation from Ajinomoto USA for organizing BCAA conference.

2 Author Disclosure: No relationships to disclose.

3 Funding for this research was provided by the Illinois Council on Food and Agricultural Research, the National Cattlemen's Beef Association, The Beef Board, and Kraft Foods.

4 To whom correspondence should be addressed. E-mail: clayman@uiuc.edu.
allowance values based on nitrogen balance. This difference highlights the important conceptual difference between requirements based on minimum levels to prevent deficiencies versus optimum levels for metabolic balance. These findings were confirmed by Pencharz and Ball (18,19), who determined rates of leucine oxidation and estimated daily leucine needs at ~8 g/d.

**Leucine regulation of muscle protein synthesis**

Unique metabolic roles for leucine were reported first for regulation of skeletal muscle protein synthesis (20). During catabolic periods, such as fasting or energy restriction, supplementation with leucine or a complete mixture of the three BCAAs leucine, isoleucine, and valine stimulates muscle protein synthesis (8,11). Likewise, leucine supplementation stimulates recovery of muscle protein synthesis after exercise (21,22). The molecular mechanisms for the actions of leucine in protein synthesis are now known to involve regulation of phosphorylation events and components of the insulin signaling pathway in translational control of muscle protein synthesis (11,23).

One site for leucine action is a kinase in the insulin signaling cascade previously identified as mammalian target of rapamycin (mTOR)5 (8,11,23). Increases in leucine concentration stimulate mTOR kinase activity for phosphorylation control of the eukaryotic initiation factor 4 complex and the S6 ribosomal protein (Fig. 1). Leucine stimulates phosphorylation of the inhibitory binding protein 4E-BP1, causing the binding protein to dissociate from the eukaryotic initiation factor 4E (eIF4E) translational initiation factor (11). Leucine stimulates activation of a second initiation factor eukaryotic initiation factor 4G (eIF4G) through an mTOR-independent kinase (11). Phosphorylated eIF4G is available to bind with free eIF4E to form the active initiation complex. Furthermore, leucine via mTOR activates p70S6 kinase, leading to phosphorylation of the S6 ribosomal protein (Fig. 1) (11,23). Mechanisms for translational regulations by leucine have been reviewed previously (11).

Molecular mechanisms for leucine stimulation of protein synthesis are supported by human studies (24–26). Short-term (2 to 4 h) intravenous infusions of large doses (3 to 7 g) of leucine produce anabolic changes in protein turnover and nitrogen balance (25,26). Likewise, leucine stimulates protein synthesis during catabolic conditions produced by short-term food deprivation or exhaustive exercise (24,27). After an overnight fast or intense exercise, protein synthesis is reduced compared with the rate of protein breakdown, producing a net breakdown of muscle protein. This catabolic period continues until adequate protein or specifically leucine is consumed to increase plasma and intracellular leucine concentrations (28). Oral intake of 2.5 g of leucine stimulates muscle protein synthesis after exercise or an overnight fast (24,27). These studies support the role of leucine as a key amino acid for reversing catabolic conditions.

Although leucine stimulates muscle protein synthesis in acute studies, the efficacy of prolonged administration is less clear. Human clinical trials with liver disease or sepsis have not produced consistent long-term benefits with leucine administration (25,26). Although these studies are complicated by the disease states, a sustained anabolic effect of leucine should be more important during catabolic periods when plasma and intracellular concentrations of leucine are reduced, such as during fasting or energy restriction for weight loss. To test this hypothesis, one approach would be to use a low protein diet control and test the effects of supplemental leucine. This approach would mimic protocols of acute studies. Unfortunately, prolonged feeding of a low protein diet supplemented with leucine increases catabolism of valine and isoleucine, producing an amino acid imbalance among the BCAAs (10).

A second experimental approach would be to feed a low protein diet and provide a balanced supplement of the three BCAAs. This approach stimulates short-term increases in protein synthesis but depletes plasma concentrations of other essential amino acids (29,30). Because of the limitations of these approaches, we elected to test the long-term potential of leucine to reduce muscle wasting during weight loss using diets with mixtures of high-quality proteins that provided >8 g/d of leucine (5).

**Protein-rich diets for treatment of obesity**

An initial concept of protein sparing during weight loss was demonstrated in a short-term study by Bistrian et al. (31). They utilized very low energy diets providing 1.5 g · kg⁻¹ · d⁻¹ of protein to produce rapid weight loss and found high protein diets reduced urinary nitrogen losses. Conclusions were reached that high protein intake was beneficial in minimizing wasting of lean tissue during weight loss for obesity.

In another short-term study, leucine infusion was shown to reduce nitrogen loss in obese subjects fasting to obtain weight loss (32). Over a 4-h period, ~3.5 g of leucine was infused, resulting in reduction of 24-h nitrogen losses. These studies suggest a higher protein diet can be beneficial during weight loss and provide evidence that protein sparing effects are largely derived from leucine.

Using these findings, we conducted two weight loss trials using diets designed to provide 10 g/d of leucine (~125 g/d of dietary protein) with a minimum of 2.5 g of leucine at each of three meals (5,33). In order to maintain equal energy intake and minimize postprandial insulin response, protein was increased proportional to the reduction in dietary carbohydrates.
In comparisons with subjects following the USDA Food Guide Pyramid, subjects consuming the protein-rich diets lost more weight and were more effective in correcting body composition during weight loss (5,33). Consumption of the protein-rich diet resulted in greater loss of body fat and attenuated loss of lean tissue consistent with a protein sparing mechanism for leucine.

We also observed changes in glucose regulations with obese subjects during weight loss (34). Subjects consuming the high carbohydrate diet (ratio of carbohydrates:protein >3.5) maintained blood glucose within the normal physiological range; however, they had a progressive decline in fasting blood glucose and increase in postprandial insulin response during the 10-wk study. These data suggest that obese subjects challenged with a high carbohydrate diet exhibit a progressive decline in glycemic control. Subjects consuming the high protein diet (carbohydrate: protein <1.5) maintained stable blood glucose with minimal changes in blood glucose or insulin from fasting to meal periods.

Similar findings have been reported by other research groups. Diets with total protein intake >1.5 g · kg⁻¹ · d⁻¹ and carbohydrate intake <150 g/d increased weight loss (1–3,6), increased loss of body fat (2,3), attenuated loss of lean tissue (1,3,7), improved glycemic control (1,3,4), reduced serum triacylglyceride levels (5,6,33,35), and reduced blood pressure (36). These diets show efficacy in catabolic conditions, such as weight loss, resulting in these clinical outcomes. The spectrum of metabolic changes seen with weight loss also have specificity for the condition known as the Metabolic Syndrome (9,36,37).

**Protein-rich diets for treatment of the metabolic syndrome**

Metabolic Syndrome or Syndrome X is a chronic disease affecting >1 in 5 adults in the U.S. It is a condition defined by glucose intolerance and compensatory hyperinsulinemia that is often observed with obesity. Specific criteria for screening and diagnosis of Metabolic Syndrome are elevated fasting blood glucose, elevated triglycerides, low HDL, abdominal obesity, and hypertension (Table 1). Presence of three of these characteristics is diagnostic for Metabolic Syndrome and highly predictive of risk for type 2 diabetes mellitus and coronary heart disease (36).

Although Metabolic Syndrome is often associated with obesity, the defining characteristic is abnormal glycemic control observed as glucose intolerance and insulin resistance (36). Stability of blood glucose requires balance between hepatic glucose release and peripheral glucose disposal. The liver regulates the rate of glucose appearance in blood by balancing absorption of dietary glucose with endogenous production of glucose from gluconeogenesis and glycogen breakdown (38,39). Use of blood glucose by peripheral tissues occurs through insulin-dependent and insulin-independent transporters (40,41). Glycemic control requires precise balance across each of the components of glycemic regulation.

### TABLE 1

| Criteria for Screening and Diagnosis of Metabolic Syndrome
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting blood glucose</td>
</tr>
<tr>
<td>Serum triglycerides</td>
</tr>
<tr>
<td>Serum HDL cholesterol</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Waist circumference</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Blood pressure</td>
</tr>
</tbody>
</table>

1 Presence of three or more of these symptoms is diagnostic (36).
kinase that is responsible for inactivation of the BCKD by phosphorylation. Inhibition of the BCKD kinase results in dephosphorylation and activation of the BCKD. The BCKD stimulates decarboxylation of the three BCAAs and commits them to oxidation. At the same time, the increase in leucine concentration also inhibits pyruvate dehydrogenase-limiting pyruvate oxidation (50). Thus, when intracellular levels of leucine are elevated, muscles use glucose derived from either the blood or glycogen stores as a glycolytic fuel and then trap the pyruvate carbon as alanine via transamination with amino acid nitrogen derived from BCAA. These mechanisms appear to be particularly important during periods of low energy intake or endurance exercise when BCAAs are increased in muscle, insulin is low, and sparing of blood glucose is important (8,14,22).

The relative importance of reducing dietary carbohydrates versus increased dietary protein for glycemic control is difficult to assess using complete diets. Both carbohydrates and protein are known to affect stability of blood glucose (51–53). Diets high in carbohydrates increase the rate of appearance of glucose into the blood and inhibit gluconeogenesis (48,54). These diets reduce the role of gluconeogenesis in management of fasting blood glucose and shift glycogenic regulation to gluconogenesis and glycogen stores (48,54). Opposite of this regulation, diets with reduced carbohydrates and increased protein increase rates of gluconeogenesis (43,48,54). Rossetti et al. (43) reported that increases in dietary protein were essential for increases in gluconeogenesis.

Clinical studies with normal and obese subjects (7,52) and individuals with type 2 diabetes (55,56) report similar findings. Using isoenergetic meals, these studies demonstrated that substituting dietary protein for carbohydrates reduced meal re-

LITERATURE CITED


11. Kimball SR, Jefferson LS. Regulation of protein synthesis by branched-


